Integrative molecular characterisation of S/R RCC to reveal determinants of poor...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
18 Feb 2020
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or ...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
18 Feb 2020
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advan...
Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom
18 Feb 2020
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients
Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec
18 Feb 2020
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and no...
Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob
14 Feb 2020
Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer
Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, ...
14 Feb 2020
BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant tre...
Dr Shilpa Gupta - Case Comprehensive Cancer Center, Cleveland, USA
14 Feb 2020
Management of patients with advanced seminoma
Prof Peter Albers - Düsseldorf University, Düsseldorf, Germany
14 Feb 2020
CHHip: Conventional versus hypofractionated high-dose intensity modulated radiot...
Prof David Dearnaley - Institute of Cancer Research, London, UK
14 Feb 2020
Latest advances in mHSPC from ASCO GU 2020
Dr Eleni Efstathiou and Prof Axel Merseburger
14 Feb 2020
ASCO GU 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
14 Feb 2020
Beyond p-values: When does clinical impact outweigh statistical significance?
Prof Matthew Sydes - University College London, London, UK
14 Feb 2020
